|
|
Post by thechurchmaus on Feb 10, 2016 15:31:36 GMT
i second that!all my remaining shares 12000 are in for appraisal. How much would you expect to get for your shares? This is not a snarky question, I just want to know if you have a dollar amount in mind? i hope to at least double my money and get 5%+ interest for the 2 years plus it takes.there is also a chance they(astellas) will try to settle.i think there might be a considerable number of shares involved.in my phone conversations with fidelity i was told that the action on ocat was unprecedented. btw as far as i know there is still time to file. |
|
|
|
Post by selluwud on Feb 10, 2016 15:33:47 GMT
OCATA = Shaman = Witchdoctor = Medicine Man = Mythical leader of a cult of followers who by the nature of the leader itself are being duped by perceived mysticism by said leader. Funny how that worked out, we should have seen it coming.
|
|
|
|
Post by harlem on Feb 10, 2016 15:42:16 GMT
Anyone know when the funds for tendered shares get deposited ty in advance and glta
|
|
|
|
Post by actcfan on Feb 10, 2016 15:43:55 GMT
As an investment into a cutting edge science goes, the lesson to be learned is only go into the ones that have sound, honest, and experienced administrative officers to lead them to success. Even at that, the phrase "caveat emptor" always applies. Agreed, lesson for me is that even the best ideas or technology can be run into the ground without proper funding and with poor management. Competent management could have really done something special with this company. Instead we got Caldwell, Rabin, and Wooton. Three blind mice. |
|
|
|
Post by actcfan on Feb 10, 2016 15:46:02 GMT
How much would you expect to get for your shares? This is not a snarky question, I just want to know if you have a dollar amount in mind? i hope to at least double my money and get 5%+ interest for the 2 years plus it takes.there is also a chance they(astellas) will try to settle.i think there might be a considerable number of shares involved.in my phone conversations with fidelity i was told that the action on ocat was unprecedented. btw as far as i know there is still time to file. I'm sorry but I don't see any possible way that this appraisal ends up higher than $8.50. They have to appraise the current value in the current (crappy) market. Any future success will be significantly discounted, no matter how strongly shareholders believe the science is can't miss. |
|
|
|
Post by vzveteran on Feb 10, 2016 15:48:33 GMT
i hope to at least double my money and get 5%+ interest for the 2 years plus it takes.there is also a chance they(astellas) will try to settle.i think there might be a considerable number of shares involved.in my phone conversations with fidelity i was told that the action on ocat was unprecedented. btw as far as i know there is still time to file. I'm sorry but I don't see any possible way that this appraisal ends up higher than $8.50. They have to appraise the current value in the current (crappy) market. Any future success will be significantly discounted, no matter how strongly shareholders believe the science is can't miss. What about the IP? It was not considered as part of the Valuation. Worth looking into if you are in no rush for the cash imo. |
|
jak
Junior Member
Pic reflects current mood
Posts: 88 
|
Post by jak on Feb 10, 2016 15:55:03 GMT
For ballpark on expectations www.appraisalrightslitigation.com/ ... “The average (median) appraisal return is 15.6% (19.6%). The average (median) length between deal completion and the appraisal decision is 1,043.1 (1,106) calendar days,” or just over three years... I hope for more than average based on IP and the fact acquiring company is outside the US and company / court is US based for all of that IP fleeing outside. |
|
|
|
Post by jckrdu on Feb 10, 2016 15:57:26 GMT
i hope to at least double my money and get 5%+ interest for the 2 years plus it takes.there is also a chance they(astellas) will try to settle.i think there might be a considerable number of shares involved.in my phone conversations with fidelity i was told that the action on ocat was unprecedented. btw as far as i know there is still time to file. I'm sorry but I don't see any possible way that this appraisal ends up higher than $8.50. They have to appraise the current value in the current (crappy) market. Any future success will be significantly discounted, no matter how strongly shareholders believe the science is can't miss. Agree. While I wish all those pursuing appraisal rights the best, I would set your expectations low for the reasons Actcfan mentions. OCAT (no trials in Phase 2) was bought out at a market cap equivalent to Mesoblast, who has multiple trials in Phase 3 and has approval thru a licensee to start generate revenues for an approved product in Japan. Given what recently happened in the biotech sector, I don't see how OCAT could be appraised at a higher value. If I were the lawyer for Astellas, I would be arguing the appraised value should be much lower.
IMO, pursuing appraisal rights seems like a waste of time and energy, as you'll continue to stay mentally connected with a disappointing situation that is likely not to bear any (or much) fruit. Sometimes the best (and healthiest) path forward is to make a clean cut with the past and move on. Staying connected with OCAT just seems like a stressful and futile exercise.
GLTA.
|
|
|
|
Post by vzveteran on Feb 10, 2016 15:59:23 GMT
From what I gathered from a respected poster on the other board, everyone from the president on down to SEC director was directly made aware of this deal.
Would someone ask if there was any meaningful reply?
|
|
|
|
Post by vzveteran on Feb 10, 2016 16:07:13 GMT
I'm sorry but I don't see any possible way that this appraisal ends up higher than $8.50. They have to appraise the current value in the current (crappy) market. Any future success will be significantly discounted, no matter how strongly shareholders believe the science is can't miss. Agree. While I wish all those pursuing appraisal rights the best, I would set your expectations low for the reasons Actcfan mentions. OCAT (no trials in Phase 2) was bought out at a market cap equivalent to Mesoblast, who has multiple trials in Phase 3 and has approval thru a licensee to start generate revenues for an approved product in Japan. Given what recently happened in the biotech sector, I don't see how OCAT could be appraised at a higher value. If I were the lawyer for Astellas, I would be arguing the appraised value should be much lower.
IMO, pursuing appraisal rights seems like a waste of time and energy, as you'll continue to stay mentally connected with a disappointing situation that is likely not to bear any (or much) fruit. Sometimes the best (and healthiest) path forward is to make a clean cut with the past and move on. Staying connected with OCAT just seems like a stressful and futile exercise.
GLTA.
Agree about the MC, but the IP has got to be worth something. If it wasn't then it wouldn't have been needed for collateral imo. MMD just got underway, technically Prior to the Merger. PW's statements about inflection points next summer fall beyond boiler plate imo. We still had cash on the books to get us there even with the delays imo. |
|
|
|
Post by selluwud on Feb 10, 2016 16:08:20 GMT
Good Luck VZ, I hope you bust their balls for a ton of money. I can't add three more years to the unfulfilling misery that has been the ACTC investment. Hell, in 3 years I may not be around to see it, so I will take my money and sit on it for a while.
|
|
|
|
Post by jckrdu on Feb 10, 2016 16:15:19 GMT
Agree. While I wish all those pursuing appraisal rights the best, I would set your expectations low for the reasons Actcfan mentions. OCAT (no trials in Phase 2) was bought out at a market cap equivalent to Mesoblast, who has multiple trials in Phase 3 and has approval thru a licensee to start generate revenues for an approved product in Japan. Given what recently happened in the biotech sector, I don't see how OCAT could be appraised at a higher value. If I were the lawyer for Astellas, I would be arguing the appraised value should be much lower.
IMO, pursuing appraisal rights seems like a waste of time and energy, as you'll continue to stay mentally connected with a disappointing situation that is likely not to bear any (or much) fruit. Sometimes the best (and healthiest) path forward is to make a clean cut with the past and move on. Staying connected with OCAT just seems like a stressful and futile exercise.
GLTA.
Agree about the MC, but the IP has got to be worth something. If it wasn't then it wouldn't have been needed for collateral imo. MMD just got underway, technically Prior to the Merger. PW's statements about inflection points next summer fall beyond boiler plate imo. We still had cash on the books to get us there even with the delays imo. I hear you Vz, but the market doesn't.
Right now the market is valuing many biotechs close to their cash on hand. Right now the market isn't assigning much value to the pipeline of many biotechs, including IP that hasn't made it into the clinic via a new trial.
IMO, Astellas is going to be making that argument when they argue against those seeking a higher appraised value. Astellas already signaled that's their view in their last PR when they indicated they would still maintain their $8.50 offer (they didn't have the option to withdraw it) even though the valuations of the biotech sector crashed.
|
|
|
|
Post by greatceasarsghost on Feb 10, 2016 16:21:18 GMT
I'm sure its been posted before, but does anyone happen to know off hand how much dough the Bored (haha) of Directors are walking away with?
|
|
|
|
Post by vzveteran on Feb 10, 2016 16:24:28 GMT
Agree with your sentiments Sell, Everyone's situation is different. I am in a position that this wasn't the milk money for me, unlike a lot of folks unfortunately.
I was able to average down some, thanks to the opinions shared here by level headed posters, hat tip to Jck.... Like I said I'll gamble with a little piece and forget I have it. Who knows, maybe It'll pan out.
|
|
|
|
Post by jckrdu on Feb 10, 2016 16:37:31 GMT
Agree with your sentiments Sell, Everyone's situation is different. I am in a position that this wasn't the milk money for me, unlike a lot of folks unfortunately. I was able to average down some, thanks to the opinions shared here by level headed posters, hat tip to Jck.... Like I said I'll gamble with a little piece and forget I have it. Who knows, maybe It'll pan out. Best of luck Vz! |
|
|
|
Post by actcfan on Feb 10, 2016 17:22:30 GMT
I'm sorry but I don't see any possible way that this appraisal ends up higher than $8.50. They have to appraise the current value in the current (crappy) market. Any future success will be significantly discounted, no matter how strongly shareholders believe the science is can't miss. What about the IP? It was not considered as part of the Valuation. Worth looking into if you are in no rush for the cash imo. I agree about the tremendous potential there but I don't think an appraisal will assign lots of value there since there is no guarantee it leads to any revenue. |
|
|
|
Post by vzveteran on Feb 10, 2016 21:40:04 GMT
|
|
|
|
Post by harlem on Feb 10, 2016 22:05:58 GMT
Can we have a thread for lawsuits for those that tendered some or all of their shares and want to join a class action suit for those that tendered but do not have appraisal rights.
Thank you
|
|
|
|
Post by vzveteran on Feb 10, 2016 22:28:24 GMT
Can we have a thread for lawsuits for those that tendered some or all of their shares and want to join a class action suit for those that tendered but do not have appraisal rights. Thank you Done |
|
|
|
Post by icellman on Feb 11, 2016 0:28:52 GMT
What an experience! This stinking stock took up 9 years of my life! By the way, I want to thank Jham for giving all of us a forum to voice our opinions. I've had my disagreements with him and Jckrdu, but in the end I ended up cutting my average cost way down, which may not have happened without their input. For that I am very grateful to them. I wish everyone the very best in their future stock endeavors! Take care everyone!
|
|
